The J.P. Morgan Healthcare Conference is a place for the well-heeled to get a readout on the next six-figure cancer drug, or learn about the gene-altering technology promising to defang a debilitating disease and send stock prices soaring.
But at this year’s conference, investors also entertained pitches from a part of the industry known more for its enduring economic problems than its profit potential: the humble primary care practice.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
